Phosphoinositide 5-phosphatase activities control cell motility in glioblastoma: Two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved

Ramos, António Manuel Pinho; Edimo, William’s Elong; Erneux, Christophé

doi:10.1016/j.jbior.2017.09.001

Cited by 43 publications

(30 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PI(4,5)P 2 can act as a signaling molecule in many biological mechanisms (e.g., endocytosis, exocytosis, migration, adhesion, ion channel control), and its content can be controlled by various members of the PI 5-phosphatase family. SHIP2, for example, can use PI(4,5)P 2 in some glioblastoma cell lines, but in others it acts mainly on PI(3,4,5)P 3 (14). The PI(4,5)P 2 dephosphorylation pathway is tremendously important in some human genetic diseases such as Lowe syndrome, which results from OCRL mutations (15), or Joubert and MORM syndromes, which result from INPP5E mutations (16).…”

mentioning

confidence: 99%

The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease

Ramos

Ghosh

Erneux

2019

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

Phosphoinositides (PIs) are recognized as major signaling molecules in many different functions of eukaryotic cells. PIs can be dephosphorylated by multiple phosphatase activities at the 5-, 4- and 3- positions. Human PI 5-phosphatases belong to a family of 10 members. Except for INPP5A, they all catalyze the dephosphorylation of PI(4,5)P2 and/or PI(3,4,5)P3 at the 5- position. PI 5-phosphatases thus directly control the levels of PI(3,4,5)P3 and also participate in fine-tuning regulatory mechanisms of PI(3,4)P2 and PI(4,5)P2. Second messenger functions have been demonstrated for PI(3,4)P2 in invadopodium maturation and in lamellipodia formation. PI 5-phosphatases can use several substrates on isolated enzymes, and it has been challenging to establish their real substrate in vivo. PI(4,5)P2 has multiple functions in signaling, including interaction with scaffold proteins, ion channels, and cytoskeleton proteins. PI 5-phosphatase isoenzymes have been individually implicated in human diseases, such as the oculocerebrorenal syndrome of Lowe, through mechanisms which include lipid-controlling. Oncogenic and tumor suppressive functions of PI 5-phosphatases have also been reported in different cell contexts. The mechanisms responsible for genetic diseases and for tumor suppressor or oncogenic functions are not fully understood. The regulation of PI 5-phosphatases is thus crucial in understanding cell functions.

show abstract

mentioning

confidence: 99%

The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease

Ramos

Ghosh

Erneux

2019

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…PIs form just a minor fraction of the total phospholipid content in eukaryotic cell membranes. However, they function in diverse roles, ranging from regulating essential biological processes such as cell adhesion [7], migration [8], apoptosis [9], vesicular trafficking [10], to post-translational modifications [11]. All these cellular processes are consistent with the hallmarks of cancer.…”

Section: Introductionmentioning

confidence: 99%

Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes

Obeng

Rusciano

Marvi

et al. 2020

IJMS

View full text Add to dashboard Cite

Phosphoinositides (PI) form just a minor portion of the total phospholipid content in cells but are significantly involved in cancer development and progression. In several cancer types, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] and phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] play significant roles in regulating survival, proliferation, invasion, and growth of cancer cells. Phosphoinositide-specific phospholipase C (PLC) catalyze the generation of the essential second messengers diacylglycerol (DAG) and inositol 1,4,5 trisphosphate (InsP3) by hydrolyzing PtdIns(4,5)P2. DAG and InsP3 regulate Protein Kinase C (PKC) activation and the release of calcium ions (Ca2+) into the cytosol, respectively. This event leads to the control of several important biological processes implicated in cancer. PLCs have been extensively studied in cancer but their regulatory roles in the oncogenic process are not fully understood. This review aims to provide up-to-date knowledge on the involvement of PLCs in cancer. We focus specifically on PLCβ, PLCγ, PLCδ, and PLCε isoforms due to the numerous evidence of their involvement in various cancer types.

show abstract

“…As KRAS has been frequently observed to be mutated in pancreatic cancer, attempts have been developed to generate effective RAS inhibitors as well as additional signaling molecules in this pathway. Attempts to inhibit the RAS/PI3K/PTEN/Akt/mTORC1/GSK-3 and other signaling pathways have been a central focus in many basic science laboratories and pharmaceutical companies for over three decades due to the involvement oncogenes in this pathway in human cancers (Yang et al, 2013;Fitzgerald et al, 2015;McCubrey et al, 2015;Anderson et al, 2016;Banfic et al, 2016;Cocco et al, 2016;Erneux et al, 2016;Falasca and Ferro, 2016;Fields et al, 2016;Geck and Toker, 2016;Maczis et al, 2016;Perdios et al, 2016;Pyne et al, 2016;Scarlata et al, 2016;Scoumanne et al, 2016;Tanaka et al, 2016;Ando et al, 2017;Carman and Han, 2017;Fujisawa, 2017;Geffken and Spiegel, 2017;Guo et al, 2017;Jang et al, 2017;Leonard and Johnson, 2017;Liu et al, 2017;Matsuzawa, 2017;McCubrey et al, 2017aMcCubrey et al, , 2017bMcCubrey et al, , 2017cMcCubrey et al, , 2017dObsil and Obsilova, 2017;Okazaki, 2017;Pyne et al, 2017;Ramos et al, 2017;Ratti et al, 2017;Rebello et al, 2017;Roth and Frohman, 2017;Rusnak and Fu, 2017;…”

Section: Introductionmentioning

confidence: 99%

Metformin influences drug sensitivity in pancreatic cancer cells

Candido

Abrams

Steelman

et al. 2018

Advances in Biological Regulation

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5-10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction of autophagy. In the following studies, we have examined the effects of metformin in the presence of various chemotherapeutic drugs, signal transduction inhibitors and natural products on the growth of three different PDAC lines. Metformin, by itself, was not effective at suppressing growth of the pancreatic cancer cell lines at concentration less than 1000 nM, however, in certain PDAC lines, a suboptimal dose of metformin (250 nM) potentiated the effects of various chemotherapeutic drugs used to treat pancreatic cancer (e.g., gemcitabine, cisplatin, 5-fluorouracil) and other cancer types (e.g., doxorubicin, docetaxel). Furthermore, metformin could increase anti-proliferative effects of mTORC1 and PI3K/mTOR inhibitors as well as natural products such as berberine and the anti-malarial drug chloroquine in certain PDAC lines. Thus, metformin can enhance the effects of certain drugs and signal transduction inhibitors which are used to treat pancreatic and various other cancers.

show abstract

Phosphoinositide 5-phosphatase activities control cell motility in glioblastoma: Two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved

Cited by 43 publications

References 66 publications

The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease

The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease

Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes

Metformin influences drug sensitivity in pancreatic cancer cells

Contact Info

Product

Resources

About